Thomas Texier - 01 Jun 2026 Form 4 Insider Report for Marex Group plc (MRX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Jun 2026, 21:30:03 UTC
Prior SEC filing
27 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Linsley as Attorney-in-Fact, for Thomas Texier

Key filing fact

Thomas Texier filed Form 4 for Marex Group plc (MRX) on 03 Jun 2026.

Key facts

  • This page summarizes Thomas Texier's Form 4 filing for Marex Group plc (MRX).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 03 Jun 2026, 21:30.

Change

  • Previous filing in this sequence was filed on 27 May 2026.
  • Current net transaction value: -$83,865.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002057414 Primary reporting owner

Texier Thomas

Relationship
Group Head of Clearing
Address
C/O MAREX GROUP PLC, 155 BISHOPSGATE, LONDON, UNITED KINGDOM
Signature
/s/ Scott Linsley as Attorney-in-Fact, for Thomas Texier
Signature date
03 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRX transaction

Ordinary Shares

Sale

Transaction value
$69,345
Shares
-1,303
Change %
-0.62%
Price
$53.22
Shares after
207,288
Date
01 Jun 2026
Ownership
Direct
Footnotes
F1, F2
MRX transaction

Ordinary Shares

Sale

Transaction value
$14,520
Shares
-269
Change %
-0.13%
Price
$53.98
Shares after
207,019
Date
01 Jun 2026
Ownership
Direct
Footnotes
F1, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.775 to $53.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $53.775 to $54.155, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The number of ordinary shares reported herein includes 150,563 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .